Pasithea Therapeutics Corp. WarrantsKTTAW
About: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Employees: 4
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more funds holding
Funds holding: 4 [Q4 2024] → 5 (+1) [Q1 2025]
13.73% less ownership
Funds ownership: 60.89% [Q4 2024] → 47.17% (-13.73%) [Q1 2025]
59% less capital invested
Capital invested by funds: $22.5K [Q4 2024] → $9.13K (-$13.4K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for KTTAW.
Financial journalist opinion
We haven’t received any recent news articles for KTTAW.